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Objectives To assess the prevalence and correlates of
self-reported genital warts (GWs) among women and
men aged 18–45 years in the Baltic countries.
Methods In 2011–2013 we performed a cross-
sectional survey using a self-administered questionnaire
to collect information on the history of clinically
diagnosed GWs, sociodemographic characteristics and
sexual behaviour. Probability sampling methods were
used to invite 16 959 individuals representing the
general population, of whom 7760 (45.8%) participated
(Estonia: 1967 women, 1221 men; Latvia: 1525
women, 1525 men; Lithuania: 1522 women).
Results The estimated lifetime prevalence of clinically
diagnosed GWs in women was 4.6% (95% CI 3.8 to
5.5) in Estonia, 2.9% (95% CI 2.0 to 3.6) in Latvia and
1.5% (95% CI 1.2 to 2.0) in Lithuania. Among men,
the corresponding values were 2.8% (95% CI 1.9 to
4.0) in Estonia and 1.9% (95% CI 1.3 to 2.6) in Latvia.
The mean age at first episode of clinically diagnosed GW
was 24.6 years (95% CI 23.6 to 25.5) for women and
24.5 years (95% CI 22.9 to 26.0) for men. A lifetime
history of clinically diagnosed GW was associated with a
history of sexually transmitted infections other than GW
(adjusted OR (AOR) 3.0, 95% CI 2.1 to 4.3 for women;
AOR 5.3, 95% CI 3.0 to 9.2 for men), and a higher
number (5+) of lifetime sexual partners (AOR 2.9, 95%
CI 1.9 to 4.2 for women; AOR 2.1, 95% CI 1.2 to 3.9
for men). Men living comfortably within their household
income had higher odds for GW (AOR 1.9, 95% CI 1.1
to 3.2).
Conclusions Our estimated prevalence of clinically
diagnosed GWs was lower than estimates from the
general population of other European countries.
INTRODUCTION
Although genital warts (GWs) rank among the
most frequent sexually transmitted infections (STIs)
their epidemiology is not well characterised.1
Human papillomavirus (HPV) types 6 and 11 cause
more than 90% of GWs.2 The quadrivalent HPV
vaccine provides protection against both these
types, and the cancer-causing types 16 and 18.3 At
the population level, GW is one of the earliest pos-
sible disease outcomes that can be measured to
assess the effectiveness of HPV vaccination pro-
grammes.4 5 Thus, regional data on the prevalence
of GWs increase the understanding of the epidemi-
ology of HPV infection, aid in the planning of
reproductive health programmes, and make an
important contribution to programme effectiveness,
analysis and decision making. Knowledge of the
overall prevalence of GW by geographical region
and sex, as well as changes in this prevalence across
different birth cohorts, are important research
areas.
A recent paper by Patel et al1 reviewed nine
studies of GW prevalence conducted since 1998 in
the general populations of Argentina, Brazil,
Australia, China, Denmark, Iceland, Norway,
Sweden, England, Scotland, Wales, Slovenia and
the USA. The lifetime prevalence estimates, based
on self-reported, clinically diagnosed GW varied
from 0.36% (Slovenia) to 12.0% (Iceland) among
women, and from 0.27% (Slovenia) to 7.9%
(Denmark) among men.1 In addition, in these
studies more women than men admitted to having
a history of GW.1
To our knowledge, data on the occurrence of
HPV-related genital disease from Central and
Eastern European countries is scant. Here, we
report a study assessing the prevalence of self-
reported clinically diagnosed GW and related
factors among 18–45-year-old women and men in
Estonia, Latvia and Lithuania before the introduc-
tion of mass vaccination programmes.
METHODS
Sampling and study population
In 2011–2013, population-based, cross-sectional
studies were conducted among women and men
aged 18–45 years from the general populations of
Estonia, Latvia, and Lithuania. The calculated
sample size needed (assuming 1% prevalence of
clinically diagnosed GW, desired precision 0.5%)
was 1522 (for men and women).
In order to obtain representative samples of the
general population, sampling methodologies were
based on the feasibility and previous experiences of
the researchers in the respective countries.6–9 In
Estonia, the National Population Registry was used
to obtain a random sample of 3804 women aged
18–45 years and 3806 men aged 18–45 years (the
sample size accounting for response rates reported
for mailed surveys).8 10
In Latvia and Lithuania, multistage stratified
probability sampling was used.
In both countries, the primary sampling units
(PSUs) were geographical regions selected with
probability proportional to size from a list stratified
by administrative-territorial region, settlement type
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(capital, other cities, rural localities) and (in Latvia only) gender.
This produced a sample of 221 PSUs in Latvia and 160 in
Lithuania. Addresses from the Population Registry of the
Latvian Office of Citizenship and Migration Affairs and the
Lithuanian State Enterprise Centre of Registers, respectively,
served as sampling frames.
Not more than 10 study subjects were recruited from each
PSU in Latvia and Lithuania. For recruitment, beginning at ran-
domly selected starting points (ie, addresses), field workers went
from door to door along a street by increasing house number,
stopping at every second house on one side of the street. During
this process field workers identified and accessed housing units
containing potentially eligible men and women aged
18–45 years: 3129 and 3479, respectively in Latvia; and 2741
(women only) in Lithuania. One eligible person per housing
unit was invited to the study using the first birthday rule (select-
ing of interviewee by the method of first coming birthday
closest to the day of survey).
Study participation was anonymous in Latvia and Lithuania,
and confidential in Estonia. The study subjects did not receive
any financial incentive for participation.
Data collection
Information about symptoms that might have been warts and on
clinically diagnosed GW (ie, GW diagnosed by a healthcare pro-
vider) and selected socioeconomic, sexual and health behaviour
characteristics (smoking history, hormonal contraceptive use,
sexual health-related healthcare visits, and history of STIs other
than GW) were collected using a structured self-administered
questionnaire, which required about 20 min to complete.11 12
In Estonia, the study questionnaire, a personalised invitation
and a prestamped, preaddressed envelope for return of the ques-
tionnaire were mailed to potential study participants. After
2 weeks, a reminder was sent to non-responders, and after
4 weeks the full package of study materials was sent again to
those who had not yet responded (reminder and second mailing
of study materials was executed based on the study-specific iden-
tification code and unlinked from the data collected from the
returned questionnaires).7 8 In Latvia and Lithuania, field
workers delivered study questionnaires and sealable envelopes;
sealed envelopes with completed questionnaires were collected
by the field workers at a time agreed with the participant (no
personally identifiable information was captured).
The study questionnaire was developed in English and then
translated into the local languages. In Estonia and Latvia all
study documents (invitations, questionnaires, informed consent
forms) were prepared in two languages (Estonian or Latvian;
and Russian). In Lithuania the study materials were produced in
Lithuanian only. The adaptation process consisted of several
steps including translation, panels of bilingual people agreeing a
‘best fit’ for the translated questionnaires, and field testing of
the resultant questionnaire (piloting) as suggested by Bhopal
et al.13 As this study required translation into more than one
language, each language version was compared with the others
to ensure comparability. In Estonia, the language of the mailed
questionnaire was based on the mother tongue information
available in the Population registry, and in Latvia on the discre-
tion of the contacted respondent.
Statistical analysis
Response rates were calculated following the guidelines from
The American Association for Public Opinion Research14 and
response rates presented were derived by dividing the number
of individuals who submitted the self-administered question-
naire by the total number of individuals invited.
Descriptive statistics were used (including mean, proportions
and range for continuous variables; percentages and absolute
frequencies for categorical variables) to summarise the data by
country and age group (≤24 years, 25–34 years, 35+ years).
The χ2 test for categorical variables was used to explore differ-
ences between groups, and the Mann-Whitney and
Kruskal-Wallis tests were used for non-normally distributed con-
tinuous variables, as appropriate.
For prevalence estimates, the proportion of participants self-
reporting clinically diagnosed GW (time frame: lifetime or last
12 months) was calculated. GW prevalence estimates were
weighted to account for non-response. The data were weighted
to be representative of the reference populations (according to
2011 censuses in Estonia, Latvia and Lithuania) by age (separ-
ately for men and women). Crude and weighted GW preva-
lences are presented together with 95% CIs.
Associations of history of GW were examined using univariate
and multivariable logistic regressions, from which ORs and
adjusted ORs (AORs), with corresponding 95% CIs, were esti-
mated. Multivariable analysis was performed separately for men
and women. Factors significantly associated with the outcome at
an α level of 0.05 were included in multivariable models. The
multivariable analysis was initially performed separately for each
country; however, because the results were very similar (data not
shown), we included all three countries in one analysis, adjusting
for country in the final statistical model. In the multivariable
logistic regression, unweighted regression estimates were used.15
RESULTS
Altogether, data on 7760 participants were collected: 3188
from Estonia (1967 women, 1221 men), 3050 from Latvia
(1525 women, 1525 men) and 1522 from Lithuania (women
only). Survey response rate was 45.8% overall: 42% in Estonia
(52% for women, 32% for men), 46% in Latvia (49% for
women, 44% for men) and 56% in Lithuania (women only).
Nearly 25% of the study participants were 24 years old or
younger, 61% were married or cohabiting (men were less likely
to be married or cohabiting than women, p<0.001), and 40%
had up to 12 years of education (men were less likely to have
≥13 years of education than women, p<0.001).
The median lifetime number of sexual partners was three for
women (SD 7.0) and five for men (SD 41.8) (women vs men
p<0.001); and the median age at first sexual intercourse was
18 years (SD 2.4; range 12–31 years) for women and 17 years
(SD 2.6; range 7–43 years) for men (women vs men p<0.001).
Seventeen per cent of women and 10% of men reported ever
having STIs other than GW (table 1).
Across the three countries, 154 women (89, 43 and 22 in
Estonia, Latvia and Lithuania, respectively) and 65 men (35 and
30 in Estonia and Latvia, respectively) reported a history of clin-
ically diagnosed GW, which translates into a (weighted) preva-
lence of 2.7% (95% CI 2.4% to 3.0%) of 18–45-year-olds in
the Baltic countries (table 1).
For women, the estimated lifetime prevalence of self-
reported, clinically diagnosed GW ranged from 4.6% (95% CI
3.8% to 5.5%) in Estonia to 1.5% (95% CI 1.2% to 2.0%) in
Lithuania. For men, the point estimate of lifetime prevalence of
self-reported, clinically diagnosed GW was slightly higher in
Estonia (2.8%, 95% CI 1.9% to 4.0%) than in Latvia (1.9%,
95% CI 1.3% to 2.6%) (p=0.12) (table 1) (online supplemen-
tary figure 1 presents age group and gender-specific estimates).
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The mean age at first episode of clinically diagnosed GW was
24.6 years (95% CI 23.6 to 25.5) for women and 24.5 years
(95% CI 22.9 to 26.0) for men, with no statistically significant
differences observed between countries or sexes.
Of the entire study sample, 0.5% (95% CI 0.4% to 0.7%) of
participants (n=44; 30 women, 14 men) reported a diagnosis of
GW within the last 12 months (women: 0.6% 95% CI 0.4% to
0.8%; men: 0.5% 95% CI 0.3% to 0.8%) (table 1).
Diagnoses of GW during the past 12 months were most fre-
quently reported in the 30–34 years age group for women (1.2%,
95% CI 0.7% to 1.9%), and men (0.8%, 95% CI 0.3% to 2.5%).
Having had sex with a partner of the same gender was
reported by 2.6% of men and 3.1% of women. The difference
in prevalence of GW (self-report, lifetime) among men report-
ing sex with men (MSM) in comparison with those exclusively
having female partner(s) (non-MSM) was close to statistical
significance (MSM vs non-MSM, 6.7% vs 2.4%, p=0.063) (of
note, only a small fraction (7%) of GW (self-report, lifetime)
reported by men were reported by MSM).
Table 2 displays factors associated with a lifetime history of
GW. We found that the most important correlate associated with
a history of GW for both sexes was a history of STIs other than
GW (AOR for women: 3.0, 95% CI 2.1 to 4.3; for men: 5.3,
95% CI 3.0 to 9.2). Lifetime number of sexual partners was
also associated with higher odds for history of GW (5+ part-
ners: women: AOR 2.9, 95% CI 1.9 to 4.2; men: AOR 2.1,
95% CI 1.2 to 3.9). Men coping or living comfortably within
their household income (AOR 1.9, 95% CI 1.1 to 3.2) had
higher odds for GW (table 2).
In a separate analysis, we analysed the possible effect of hor-
monal contraceptive use on history of clinically diagnosed GW.
In our data, previous hormonal contraceptive use was not
Table 1 Sociodemographic, sexual and healthcare behaviour characteristics, and the prevalence of self-reported, clinically diagnosed genital
warts among women and men aged 18–45 years in the Baltic countries in 2011–2013
All (N=7760) Estonia (n=3188) Latvia (n=3050)
Lithuania
(n=1522)









n Per cent n Per cent Per cent Per cent Per cent Per cent Per cent
Age (years)
18–19 181 7 262 5 4 2 11 9 5
20–24 579 21 906 18 20 16 26 18 20
25–29 479 17 850 17 16 16 16 16 16
30–34 421 15 846 17 14 18 14 16 17
35–39 438 16 854 17 19 20 11 13 15
40+ 648 24 1296 26 27 27 22 29 27
Married or cohabiting 1517 55 3206 64 65 74 44 56 59
Ethnicity (main*) 1889 69 3831 76 77 76 63 65 88




1208 45 2336 47 36 38 51 58 49
Ever smoked 1881 69 2315 46 67 48 69 47 45
Age at first sexual
intercourse ≤15 years
456 18 487 10 18 13 20 9 7
Lifetime number of
sexual partners ≥5
1281 53 1480 33 55 44 51 30 20
History of STI other
than genital warts
(yes)†
269 10 856 17 13 29 7 12 7
Reproductive/genital
healthcare visit (ever)




NA NA 1205 43 NA 73 NA 55 51
Ever thought they had a lump or a bump that might have been a genital wart, n, % (95% CI)
Crude prevalence 166 6.0 (5.2 to 7.0) 353 7.0 (6.4 to 7.8) 8.0 (6.6 to 9.7) 10.1 (8.9 to 11.5) 4.5 (3.5 to 5.6) 5.2 (4.2 to 6.5) 4.9 (3.9 to 6.1)
Weighted prevalence 149 5.8 (4.9 to 6.7) 497 6.8 (6.3 to 7.4) 8.1 (6.5 to 10.0) 10.2 (9.1 to 11.4) 4.4 (3.5 to 5.5) 5.2 (4.2 to 6.4) 4.9 (4.2 to 5.7)
Self-reported history of clinically diagnosed genital warts during lifetime, n, % (95% CI)
Crude prevalence 65 2.4 (1.9 to 3.0) 154 3.1 (2.6 to 3.6) 2.9 (2.1 to 4.0) 4.5 (3.7 to 5.5) 2.0 (1.4 to 2.8) 2.8 (2.1 to 3.8) 1.4 (0.9 to 2.2)
Weighted prevalence 57 2.2 (1.7 to 2.9) 208 2.9 (2.5 to 3.3) 2.8 (1.9 to 4.0) 4.6 (3.8 to 5.5) 1.9 (1.3 to 2.6) 2.9 (2.0 to 3.6) 1.5 (1.2 to 2.0)
Self-reported history of clinically diagnosed genital warts during the last 12 months, n, % (95% CI)
Crude prevalence 14 0.5 (0.3 to 0.9) 30 0.6 (0.4 to 0.9) 0.7 (0.3 to 0.9) 0.8 (0.5 to 1.3) 0.4 (0.2 to 0.9) 0.6 (0.3 to 1.1) 0.4 (0.2 to 0.9)
Weighted prevalence 12 0.5 (0.3 to 0.8) 41 0.6 (0.4 to 0.8) 0.6 (0.3 to 1.3) 0.8 (0.5 to 1.2) 0.4 (0.2 to 0.8) 0.6 (0.3 to 1.1) 0.4 (0.2 to 0.7)
*Main ethnic group: Estonians, Latvians, Lithuanians.
†STI, sexually transmitted infection; includes genital chlamydial infection, gonorrhoea, trichomoniasis, herpes and/or syphilis ever diagnosed by a physician (does not include HIV
infection).
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associated with a history of GW (AOR 1.1 (vs never), 95% CI
0.8 to 1.6) (data not shown).
DISCUSSION
In this population-based study of nearly 7800 women and men
aged 18–45 years, we found that the lifetime prevalence of self-
reported, clinically diagnosed GW ranged among women from
4.6% (95% CI 3.7% to 5.5%) in Estonia to 2.9% (95% CI
2.1% to 3.8%) in Latvia and 1.5% (95% CI 0.9% to 2.2%) in
Lithuania; and for men from 2.8% (95% CI 1.9% to 4.0%) in
Estonia to 1.9% (95% CI 1.3% to 2.6%) in Latvia.
The self-reported prevalence of clinically diagnosed GW dif-
fered across the three Baltic countries. Yet, the reported preva-
lences were lower than those reported from Nordic countries
(10% among women aged 18–45 years),11 the UK (among sexu-
ally experienced 18–44 year-old women 4.1% and men
3.6%),16 Denmark (7.9% men aged 18–45 years)17 or the USA
(7.2% among women, 4% among men aged 18–59 years).18
Published data on the prevalence of GW from Central and
Eastern European countries is limited. Very low lifetime preva-
lence of self-reported GWs among sexually experienced 18–
49-year-old women (0.4%) and men (0.3%) in Slovenia has
been reported.19
There are likely many factors that account for the lower life-
time prevalence of GWobserved in this study in Baltic countries
compared with Western European countries. GW is caused by
HPV, which is almost exclusively transmitted by sexual inter-
course, and therefore the lower prevalence of GW in Estonia,
Latvia and Lithuania could be explained by differences in sexual
behaviour. The median lifetime number of sexual partners
reported by women in the Baltic countries was three, compared
with the five reported by women in Nordic countries. Age at
first sexual intercourse in women was also higher in the Baltic
Table 2 The prevalence of and factors associated with reporting ever receiving a clinical diagnosis of genital warts for women and men aged
18–45 years in the Baltic countries in 2011–2013
Men Women
% (95% CI) OR (95% CI) AOR* (95% CI) % (95% CI) OR (95% CI) AOR† (95% CI)
Country
Estonia 2.9 (2.1 to 4.0) 1 1 4.5 (3.7 to 5.5) 3.1 (2.2 to 4.3) 1.6 (1.0 to 2.6)
Latvia 2.0 (1.4 to 2.8) 0.6 (0.4 to 1.1) 0.9 (0.5 to 1.5) 2.8 (2.1 to 3.8) 1.8 (1.2 to 2.7) 1.4 (0.8 to 2.4)
Lithuania na na na 1.5 (1.0 to 2.2) 1 1
Age (years)
≤24 0.9 (0.5 to 1.9) 0.2 (0.1 to 0.6) 0.6 (0.3 to 1.6) 1.5 (0.9 to 2.3) 0.4 (0.2 to 0.6) 0.7 (0.4 to 1.3)
25–34 3.0 (2.1 to 4.3) 1 (0.6 to 1.8) 1.2 (0.7 to 2.2) 4.1 (3.2 to 5.1) 1.3 (1.0 to 1.7) 1.3 (0.9 to 1.9)
35+ 2.9 (2.0 to 4.0) 1 1 3.2 (2.5 to 4.0) 1 1
Education
≤12 years 2.0 (1.4 to 2.9) 0.7 (0.4 to 1.2) na 2.9 (2.2 to 3.8) 1 (0.8 to 1.4) na
13+ years 2.8 (2.0 to 3.9) 1 na 3.1 (2.6 to 3.8) 1 na
Marital status
Married or cohabiting 2.8 (2.1 to 3.8) 1.9 (1.1 to 3.3) 0.9 (0.5 to 1.6) 3.2 (2.7 to 3.9) 1.2 (0.9 to 1.6) na
Other 1.8 (1.2 to 2.7) 1 1 2.8 (2.1 to 3.6) 1 na
Ethnicity
Main 2.5 (1.9 to 3.4) 1.3 (0.7 to 2.4) na 3.0 (2.5 to 3.6) 0.9 (0.6 to 1.2) na
Other 2.0 (1.3 to 3.2) 1 na 3.3 (2.4 to 4.5) 1 na
Employment
Employed 2.6 (2.0 to 3.5) 1.7 (0.9 to 3.1) na 3.3 (2.8 to 4.0) 1.3 (0.9 to 1.7) na
Other 1.7 (1.0 to 2.8) 1 na 2.6 (2.0 to 3.4) 1 na
Coping with household income
Living comfortably or coping 2.9 (2.2 to 3.9) 1.8 (1.0 to 3.2) 1.9 (1.1 to 3.2) 3.9 (3.2 to 4.8) 1.2 (0.9 to 1.6) na
Difficult or very difficult 1.7 (1.1 to 2.5) 1 1 2.7 (2.2 to 3.5) 1 na
Smoking
Ever 2.6 (2.0 to 3.4) 1.5 (0.8 to 2.7) na 3.9 (3.2 to 4.8) 1.8 (1.4 to 2.4) 1.1 (0.8 to 1.7)
Never 1.8 (1.1 to 2.9) 1 na 2.4 (1.8 to 3.0) 1 1
Age at first sexual intercourse
≤15 years 3.1 (1.8 to 5.1) 1.3 (0.7 to 2.4) na 5.5 (3.8 to 8.0) 1.9 (1.3 to 2.8) 1.2 (0.8 to 1.9)
16+ years 2.5 (1.9 to 3.2) 1 na 3.0 (2.5 to 3.5) 1 1
Lifetime number of sexual partners
5 or more 3.8 (2.9 to 5.0) 3.0 (1.6 to 5.6) 2.1 (1.2 to 3.9) 6.6 (5.5 to 8.0) 4.5 (3.3 to 6) 2.9 (1.9 to 4.2)
0–4 1.3 (0.8 to 2.2) 1 1 1.6 (1.2 to 2.1) 1 1
History of STI other than genital warts‡
Yes 9.3 (6.4 to 13.4) 7.4 (4.3 to 12.9) 5.3 (3.0 to 9.2) 8.8 (7.1 to 10.8) 5.3 (4.0 to 7.1) 3.0 (2.1 to 4.3)
No 1.6 (1.2 to 2.2) 1 1 1.9 (1.5 to 2.4) 1 1
*Adjusted for country, age, the number of lifetime sexual partners, ever having STI, marital status, coping with present household income.
†Adjusted for country, age, the number of lifetime sexual partners, ever having STI, smoking, age at first sex.
‡Genital chlamydial infection, gonorrhoea, trichomoniasis, herpes and syphilis (does not include HIV infection).
STI, sexually transmitted infection.
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countries (18 years of age) compared with Nordic countries
(16 years)11; 43% of men in Denmark reported having had
sexual intercourse with 10 or more female partners during their
lifetime,17 compared with 28% of men in the Baltic studies
(data not shown). Health surveys conducted in representative
samples of the general populations of Baltic countries have
shown a lower lifetime number of sexual partners compared
with Western European countries.20 For example, in the UK the
British National Survey of Sexual Attitudes and lifestyles
(NATSAL) study,21 about 30% of women and 40% of men aged
25–44 years reported 10 or more sexual partners in their life-
time. In a similar study from Estonia, the proportion of women
reporting over 10 sexual partners was slightly over 10%,20
which fits well with our results of 11.2%.
The observed lower reported prevalence of GW in Baltic
countries compared with Western European countries (similar
to the lower rates observed in a separate study in Slovenia19)
could also reflect differences in public awareness and/or the spe-
cialty of the physicians making the diagnosis, as well as differ-
ences in healthcare systems (access to STI/genital health
services).6
Few studies of HPV seroprevalence in Central/Eastern
European countries with low GW occurrence22 23 have docu-
mented HPV6 and HPV11 seroprevalence that are comparable
with studies from Western European countries.24 25
Unfortunately we were unable to find any HPV6 or HPV11
seroprevalence studies from the three Baltic countries.
Furthermore, last 12 months prevalence of GW in the Baltic
countries was reported most often by women and men aged
30–34 years. In a study from four Nordic countries, GW diag-
nosed within the previous 12 months were most frequently
reported by women aged up to 25 years.11 In men in the three
Baltic countries, the 12 month prevalence of clinically diagnosed
GW increases markedly between the ages of 20 years and 24 years
and remains high in those aged 35–39 years. In comparison,
among men in Denmark, the 12-month GW prevalence is highest
among young men (aged 21–24 years) but decreases thereafter and
is very low in men aged 35 years and over.17 According to the
limited information available on HPV prevalence in the Baltic
countries, the highest prevalence of low-risk HPV types are found
among women under 25years of age8—an observation that
mirrors similar studies from Western European countries.26 27
The factors associated with the prevalence of GWobserved in
our study are in line with those from other studies. GW is
related to high-risk sexual behaviour (history of a STI other
than GW or high lifetime number of sexual partners).
Traditionally lower income and educational levels have been
associated with increased risks for contracting STIs.28 The
higher prevalence of GW among men coping or living comfort-
ably within their household income might be related to the cap-
acity to recognise GW as a health problem, and the ability and
willingness of this group to seek treatment.
Our study has limitations. We used self-reported history of
GWas a basis for prevalence estimations. Self-reported measures
have been questioned as a reliable source for assessing occur-
rence. We acknowledge this limitation, yet self-reporting on GW
has been used in several studies across Western Europe11 16 and
the USA,18 and we believe that for comparison purposes our
results are still valid and of importance. To assure higher specifi-
city we based our prevalence measure on clinically diagnosed
episodes of GW. Intuitively, this may imply that the estimated
occurrence is most likely an underestimate. Other potential
sources of bias associated with the sensitive behaviours and out-
comes under investigation are socially desirable responses and
recall bias. Further, our results might be influenced by the
modest participation rate. Usually the lower the participation
rate the higher the STI prevalence (eg, chlamydia) reported
from the study29 and study participants are more likely to have
a STI-related diagnosis/healthcare visit than non-participants.8
In the analysis of factors associated with GW, rather robust mea-
sures of behavioural and health indicators were used (smoking,
hormonal contraceptive use). We used a self-administered survey
format with the aim of maximising participation rate and
sample size(s), but we recognise that this limited the use of
detailed and multifaceted exposure measures. Different sam-
pling methodologies were used in participating countries to
accrue a population-based sample (stratified random sampling in
Estonia; multistage stratified area probability in Latvia and
Lithuania). It is hard to interpret how this might have influenced
the study results. To minimise non-response bias the prevalence
estimates were weighted to ensure representativeness of the
source population. Last but not the least, the cross-sectional
study design does not allow us to meaningfully answer the ques-
tion of whether the lower observed prevalence of GW in Baltic
countries (than in Western European countries (developed coun-
tries)) is an accurate description of the disease level in the popu-
lation, or an attribute of the study design and/or awareness and
diagnosis of the disease in the population. Use of a strict defin-
ition (of clinically diagnosed GW) rather than self-reported
‘genital lumps and bumps’ could mean that undiagnosed cases
of GW were missed, and therefore the true prevalence of GW
may have been higher. However, we believe self-reporting of
genital ‘lumps and bumps’ is not specific for GW given the fre-
quent occurrence of ‘lumps and bumps’ that may wrongly be
identified by patients as GW but, in fact, are normal anatomical
structures (eg, pearly penile papules, parafrenular glands,
Fordyce spots, vestibular papillae) or other conditions, including
infectious diseases (such as molluscum).
The strengths of this study include being the only study to
date on the prevalence of GW in the Baltic countries (ie, coun-
tries in Europe with a high cervical cancer incidence and mortal-
ity). It also has the advantage of being nationwide and based on
a random probability sample of participants from the general
population.
Our study contributes to the knowledge base of the epidemi-
ology of HPV disease in the population in different regions.
Better understanding of the variations and trends in genital
HPV disease by the different regions of the world can provide
important clues to aetiology and prevention efforts. Further,
such data can be useful for public health decision making by
providing a baseline for prevaccination status and a basis for
assessing the potential burden of genital HPV that can be pre-
vented by vaccination programmes.
Key messages
▸ The prevalence of self-reported genital wart diagnosis in
Baltic countries was lower than those reported from
comparable studies from Western European countries.
▸ This difference may reflect regional differences in sexual
behaviour.
▸ The difference may also reflect differences in public
awareness and/or the specialty of physicians making the
diagnosis, as well as differences in healthcare systems.
Epidemiology
Uusküla A, et al. Sex Transm Infect 2015;91:55–60. doi:10.1136/sextrans-2014-051540 59
 on N
ovem













Handling editor Jackie A Cassell
Acknowledgements The authors thank Iveta Pudule, the head of the Latvian
Public Health Association for her consultancy in data collection in Latvia.
Contributors AU, RR and MN designed the study and RR, AK, DR, ZL and ZP
organised and secured the data collection, data entry. AU and RR planned the
analysis; RR organised the data for analysis and conducted the statistical analysis.
AU wrote the first draft of the manuscript. All authors contributed to revising the
manuscript and have approved the final manuscript.
Funding This study was funded by the Investigator initiated programme MISP
#38078 from Merck. MN has received, through the affiliating institute, a research
grant from MSD Norway.
Competing interests None
Patient consent Obtained.
Ethics approval The necessary ethical approval was secured prior to the initiation
of the studies in each country (Estonia: Research Ethics Committee of the University
of Tartu; Latvia: Central Medical Ethics Committee of Latvia (under the Ministry of
Health); Lithuania: Kaunas Regional Biomedical Research Ethics Committee 2012-
05-14, 2013-01-07).
Provenance and peer review Not commissioned; externally peer reviewed.
REFERENCES
1 Patel H, Wagner M, Singhal P, et al. Systematic review of the incidence and
prevalence of genital warts. BMC Infect Dis 2013;13:39.
2 Lacey CJ, Lowndes CM, Shah KV. Chapter 4: Burden and management of
non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006;
24(Suppl 3):S3/35–41.
3 Munoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6/
11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl
Cancer Inst 2010;102:325–39.
4 Donovan B, Franklin N, Guy R, et al. Quadrivalent human papillomavirus
vaccination and trends in genital warts in Australia: analysis of national sentinel
surveillance data. Lancet Infect Dis 2011;11:39–44.
5 Leval A, Herweijer E, Ploner A, et al. Quadrivalent human papillomavirus vaccine
effectiveness: a Swedish national cohort study. J Natl Cancer Inst
2013;105:469–74.
6 Mozaļevskis A, Freimane A, Upmace I, et al. Eiropas interneta pētījums par
vīriešiem,kuriem ir dzimumattiecības ar vīriešiem (EMIS), Pētījuma rezultāti. Latvija
Rīga 2013:36.
7 Pärna K, Rahu K, Helakorpi S, et al. Alcohol consumption in Estonia and Finland:
Finbalt survey 1994–2006. BMC Public Health 2010;10:261.
8 Uusküla A, Kals M, McNutt L-A. Assessing non-response to a mailed health survey
including self-collection of biological material. Eur J Public Health 2011;21:538–42.
9 Miškinis K, Riklikienė O, Kalėdienė R, et al. Lietuvos gyventojų informuotumas ir
pasitikėjimas privalomojo sveikatos draudimo sistema. Sveikatos Mokslai
2011;21:48–61.
10 Prattala R, Paalanen L, Grinberga D, et al. Gender differences in the consumption
of meat, fruit and vegetables are similar in Finland and the Baltic countries. Eur J
Public Health 2007;17:520–5.
11 Kjaer SK, Tran TN, Sparen P, et al. The burden of genital warts: a study of nearly
70,000 women from the general female population in the 4 Nordic countries.
J Infect Dis 2007;196:1447–54.
12 Amon J, Brown T, Hogle J, et al. Behavioural Surveillance Surveys. BSS Guidelines
for repeated behavioural surveys in populations at risk of HIV: Family Health
International. 2000.
13 Bhopal R, Vettini A, Hunt S, et al. Review of prevalence data in, and evaluation of
methods for cross cultural adaptation of, UK surveys on tobacco and alcohol in
ethnic minority groups. BMJ 2004;328:5.
14 AAPOR. Standard definitions: final dispositions of case codes and outcome rates for
surveys. 7th edn. The American Association for Public Opinion Research, 2011.
15 Winship C, Radbill L. Sampling weights and regression analysis. Sociol Methods Res
1994;23:230–57.
16 Fenton KA, Korovessis C, Johnson AM, et al. Sexual behaviour in Britain: reported
sexually transmitted infections and prevalent genital Chlamydia trachomatis
infection. Lancet 2001;358:1851–4.
17 Munk C, Nielsen A, Liaw KL, et al. Genital warts in men: a large population-based
cross-sectional survey of Danish men. Sex Transm Infect 2012;88:640–4.
18 Dinh TH, Sternberg M, Dunne EF, et al. Genital warts among 18- to 59-year-olds in
the United States, national health and nutrition examination survey, 1999–2004.
Sex Transm Dis 2008;35:357–60.
19 Klavs I, Grgic-Vitek M. The burden of genital warts in Slovenia: results from a
national probability sample survey. Euro Surveill 2008;13:19032.
20 Part K, Laanpere M, Rahu K, et al. Estonian women’s health: sexual and
reproductive health, health behavior, attitudes and use of health care services
Survey report. Tartu 2007.
21 Mercer CH, Tanton C, Prah DP, et al. Changes in sexual attitudes and lifestyles in
Britain through the life course and over time: findings from the National Surveys of
Sexual Attitudes and Lifestyles (Natsal). Lancet 2013;382:1781–94.
22 Fait T, Dvorak V, Skrivanek A, et al. [Epidemiology of genital warts in female
population of Czech Republic]. Ceska Gynekol 2012;77:360–3.
23 Hamsikova E, Ludvikova V, Stasikova J, et al. Cross-sectional study on the
prevalence of HPV antibodies in the general population of the Czech Republic. Sex
Transm Infect 2013;89:133–7.
24 Desai S, Chapman R, Jit M, et al. Prevalence of human papillomavirus antibodies in
males and females in England. Sex Transm Dis 2011;38:622–9.
25 Skjeldestad FE, Mehta V, Sings HL, et al. Seroprevalence and genital DNA
prevalence of HPV types 6, 11, 16 and 18 in a cohort of young Norwegian
women: study design and cohort characteristics. Acta Obstet Gynecol Scand
2008;87:81–8.
26 Sargent A, Bailey A, Almonte M, et al. Prevalence of type-specific HPV infection by
age and grade of cervical cytology: data from the ARTISTIC trial. Br J Cancer
2008;98:1704–9.
27 Kjaer SK, Breugelmans G, Munk C, et al. Population-based prevalence, type- and
age-specific distribution of HPV in women before introduction of an
HPV-vaccination program in Denmark. Int J Cancer 2008;123:1864–70.
28 Harling G, Subramanian S, Barnighausen T, et al. Socioeconomic disparities in
sexually transmitted infections among young adults in the United States: examining
the interaction between income and race/ethnicity. Sex Transm Dis 2013;40:575–81.
29 Low N, Forster M, Taylor SN, et al. Repeat chlamydia screening among adolescents:
cohort study in a school-based programme in New Orleans. Sex Transm Infect
2013;89:20–4.
Epidemiology
60 Uusküla A, et al. Sex Transm Infect 2015;91:55–60. doi:10.1136/sextrans-2014-051540
 on N
ovem








 Infect: first published as 10.1136/sextrans-2014-051540 on 7 A
ugust 2014. D
ow
nloaded from
 
